Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD

NCT02727660 is registered in ClinicalTrials.gov with Pearl Therapeutics, Inc. as lead sponsor.

NCT NCT02727660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02727660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD
Lead sponsor
Pearl Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 29, 2016
Completion date
April 4, 2018
Enrollment
1,876 (actual)
Sites
282

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disorder